002100.SZ
天康生物
SZSE · Consumer Defensive · C 制造业 · CN
CNY 7.17
+0.28%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 16.7B | 17.0B | 17.2B | 19.0B | 17.0B |
| Cost of Revenue | 15.4B | 15.3B | 15.1B | 18.5B | 15.3B |
| Gross Profit | 1.3B | 1.7B | 2.1B | 556.4M | 1.7B |
| Operating Expenses | |||||
| R&D Expense | 170.6M | 183.5M | 200.3M | 257.2M | 179.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 511.9M | 517.1M | 559.6M | 486.7M | 477.8M |
| Selling & Marketing Expense | 367.7M | 381.3M | 427.6M | 543.1M | 493.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.2B | 1.3B | 1.4B | 1.5B | 1.4B |
| Cost and Expenses | 16.6B | 16.6B | 16.5B | 20.0B | 16.7B |
| Operating Income (EBIT) | 12.5M | 322.2M | 631.1M | (1.4B) | 256.8M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (8.1M) | 328.1M | 610.8M | (1.5B) | 216.0M |
| Income Tax Expense | 35.5M | 27.8M | 14.4M | 23.5M | 26.0M |
| Bottom Line | |||||
| Net Income | (100.8M) | 210.6M | 605.1M | (1.4B) | 280.8M |
| Earnings from Cont. Ops | (43.6M) | 300.3M | 596.4M | (1.5B) | 190.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (100.8M) | 210.6M | 605.1M | (1.4B) | 280.8M |
| Per Share | |||||
| Basic EPS | (CN¥0.07) | CN¥0.15 | CN¥0.44 | (CN¥1.01) | CN¥0.21 |
| Diluted EPS | (CN¥0.07) | CN¥0.15 | CN¥0.44 | (CN¥1.01) | CN¥0.21 |
| Revenue Per Share | CN¥12.29 | CN¥12.09 | CN¥12.49 | CN¥14.10 | CN¥12.71 |
| Shares | |||||
| Basic Shares Outstanding | 1.4B | 1.4B | 1.4B | 1.3B | 1.3B |
| Diluted Shares Outstanding | 1.4B | 1.4B | 1.4B | 1.3B | 1.3B |
| Profitability Metrics | |||||
| EBITDA | — | 996.8M | 1.4B | (632.0M) | 982.5M |
| D&A | — | 674.6M | 724.2M | 814.0M | 725.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026